Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer

[1]  P. Gándara-Vila,et al.  Oral Chronic Hyperplastic Candidiasis and Its Potential Risk of Malignant Transformation: A Systematic Review and Prevalence Meta-Analysis , 2022, Journal of fungi.

[2]  Y. Chao,et al.  Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  J. W. Kim,et al.  Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. , 2022, NEJM evidence.

[4]  Qian Li,et al.  Toripalimab in advanced biliary tract cancer , 2022, Innovation (Cambridge (Mass.)).

[5]  B. El-Rayes,et al.  Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers , 2022, Cancers.

[6]  Xueda Hu,et al.  Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer , 2021, Nature Cancer.

[7]  R. Shroff,et al.  Current and emerging therapies for advanced biliary tract cancers. , 2021, The lancet. Gastroenterology & hepatology.

[8]  A. Biankin,et al.  Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Giacomantonio,et al.  Mast Cells and Skin and Breast Cancers: A Complicated and Microenvironment-Dependent Role , 2021, Cells.

[10]  Y. Shu,et al.  Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer , 2021, OncoTargets and therapy.

[11]  G. Brandi,et al.  Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer , 2021, Expert review of gastroenterology & hepatology.

[12]  R. Berger,et al.  Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. , 2021, Gastroenterology.

[13]  J. Becker,et al.  Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy , 2021, Nature communications.

[14]  E. Engleman,et al.  Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. , 2020, Annual review of pathology.

[15]  Xuehao Wang,et al.  Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial , 2020, Journal for ImmunoTherapy of Cancer.

[16]  Anil Singh,et al.  Tumor associated mast cells: biological roles and therapeutic applications , 2020, Anatomy & cell biology.

[17]  A. Tafreshi,et al.  A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  A. Loskog,et al.  The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses , 2020, Frontiers in Immunology.

[19]  N. Utku,et al.  A review of systemic therapy in biliary tract carcinoma. , 2020, Journal of gastrointestinal oncology.

[20]  M. Schell,et al.  A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. , 2020, JAMA oncology.

[21]  Q. Mei,et al.  Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study , 2020, Journal for immunotherapy of cancer.

[22]  I. Witz,et al.  The Tumor Microenvironment , 2012 .

[23]  J. Lee,et al.  Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. , 2019, JAMA oncology.

[24]  H. Katayama,et al.  Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) Randomized Phase III Clinical Trial. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  V. Sreenivas,et al.  Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial. , 2019, European journal of cancer.

[26]  L. Fournel,et al.  Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. , 2019, Cancer letters.

[27]  J. Furuse,et al.  Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. , 2019, The lancet. Gastroenterology & hepatology.

[28]  F. Redegeld,et al.  Role of Mast Cells in Shaping the Tumor Microenvironment , 2019, Clinical Reviews in Allergy & Immunology.

[29]  M. Borad,et al.  Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. , 2019, JAMA oncology.

[30]  W. Woodward,et al.  Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer , 2019, Cancer Immunology Research.

[31]  S. Oh,et al.  Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Jingting Jiang,et al.  Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer , 2019, Front. Immunol..

[33]  D. Felsher,et al.  The MYC oncogene is a global regulator of the immune response. , 2018, Blood.

[34]  Han Liu,et al.  Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients , 2018, BMC Cancer.

[35]  Jia Gu,et al.  fastp: an ultra-fast all-in-one FASTQ preprocessor , 2018, bioRxiv.

[36]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[37]  Marina N Nikiforova,et al.  Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[38]  M. Frey,et al.  Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature , 2017, Gynecologic Oncology Research and Practice.

[39]  Quan Li,et al.  InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. , 2017, American journal of human genetics.

[40]  J. Lunceford,et al.  IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade , 2017 .

[41]  Y. Drew,et al.  Homologous recombination deficiency and ovarian cancer. , 2016, European journal of cancer.

[42]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[43]  O. Hofmann,et al.  VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research , 2016, Nucleic acids research.

[44]  Christopher P. Johnson,et al.  Inhibition of Mast Cell-Derived Histamine Decreases Human Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factor-Dependent Signaling. , 2016, The American journal of pathology.

[45]  Joon-Oh Park,et al.  Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review , 2015, Cancer research and treatment : official journal of Korean Cancer Association.

[46]  Alexander Gutin,et al.  Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes , 2014, Breast Cancer Research.

[47]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[48]  X. Zou,et al.  Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells. , 2014, International immunopharmacology.

[49]  A. Warth,et al.  Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer , 2013, British Journal of Cancer.

[50]  Jason B. Williams,et al.  Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.

[51]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[52]  M. Miyazaki,et al.  Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan , 2010, British Journal of Cancer.

[53]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[54]  M. Mihm,et al.  Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. , 2010, American journal of clinical pathology.

[55]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[56]  M. Tretiakova,et al.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. , 2009, Cancer research.

[57]  T. Dønnem,et al.  Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[58]  A. R.,et al.  Review of literature , 1969, American Potato Journal.

[59]  S. Curley,et al.  Biliary tract cancer. , 1997, Cancer treatment and research.

[60]  D. Schoenfeld,et al.  Sample-size formula for the proportional-hazards regression model. , 1983, Biometrics.